Sur la bonne voie - ACHAT - OC 16€
La société a communiqué des résultats 2016 solides alliant croissance, approche de la rentabilité en année pleine et absence de besoins de financement. Le groupe renforce son statut « best-in-class » français du marché des fractures vertébrales. Nous abaissons nos estimations d’OPEX en 2017 car aucun coût ne devrait être affecté à la zone US. 2017 sera une année riche avec des résultats cliniques capitaux pour l’expansion aux US, l’ouverture de nouveaux pays et la poursuite de la pénétration du marché allemand. Recommandation ACHAT et objectif inchangé de 16€.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.